160 related articles for article (PubMed ID: 14693409)
1. Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects.
Yatagai T; Nakamura T; Nagasaka S; Kusaka I; Ishikawa SE; Yoshitaka A; Ishibashi S
Diabetes Res Clin Pract; 2004 Jan; 63(1):19-26. PubMed ID: 14693409
[TBL] [Abstract][Full Text] [Related]
2. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
Yu JG; Kruszynska YT; Mulford MI; Olefsky JM
Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
[TBL] [Abstract][Full Text] [Related]
3. Serum leptin level as an indicator to predict the clinical efficacy of troglitazone in patients with type 2 diabetes mellitus.
Maruyama S; Yanagisawa K; Kanamuro R; Teno S; Iwamoto Y
Diabetes Res Clin Pract; 2001 Sep; 53(3):161-4. PubMed ID: 11483231
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
Chu NV; Kong AP; Kim DD; Armstrong D; Baxi S; Deutsch R; Caulfield M; Mudaliar SR; Reitz R; Henry RR; Reaven PD
Diabetes Care; 2002 Mar; 25(3):542-9. PubMed ID: 11874944
[TBL] [Abstract][Full Text] [Related]
5. Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects.
Ciaraldi TP; Kong AP; Chu NV; Kim DD; Baxi S; Loviscach M; Plodkowski R; Reitz R; Caulfield M; Mudaliar S; Henry RR
Diabetes; 2002 Jan; 51(1):30-6. PubMed ID: 11756319
[TBL] [Abstract][Full Text] [Related]
6. Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione.
Kautzky-Willer A; Tura A; Winzer C; Wagner OF; Ludvik B; Hanusch-Enserer U; Prager R; Pacini G
Diabetes Obes Metab; 2006 Sep; 8(5):561-7. PubMed ID: 16918591
[TBL] [Abstract][Full Text] [Related]
7. Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes.
Ebeling P; Teppo AM; Koistinen HA; Viikari J; Rönnemaa T; Nissén M; Bergkulla S; Salmela P; Saltevo J; Koivisto VA
Diabetologia; 1999 Dec; 42(12):1433-8. PubMed ID: 10651262
[TBL] [Abstract][Full Text] [Related]
8. Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus.
Prigeon RL; Kahn SE; Porte D
J Clin Endocrinol Metab; 1998 Mar; 83(3):819-23. PubMed ID: 9506734
[TBL] [Abstract][Full Text] [Related]
9. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects.
Kim YB; Ciaraldi TP; Kong A; Kim D; Chu N; Mohideen P; Mudaliar S; Henry RR; Kahn BB
Diabetes; 2002 Feb; 51(2):443-8. PubMed ID: 11812753
[TBL] [Abstract][Full Text] [Related]
10. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
[TBL] [Abstract][Full Text] [Related]
11. Troglitazone and metformin, but not glibenclamide, decrease blood pressure in Otsuka Long Evans Tokushima Fatty rats.
Kosegawa I; Chen S; Awata T; Negishi K; Katayama S
Clin Exp Hypertens; 1999 Apr; 21(3):199-211. PubMed ID: 10225476
[TBL] [Abstract][Full Text] [Related]
12. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
Kumar S; Prange A; Schulze J; Lettis S; Barnett AH
Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807
[TBL] [Abstract][Full Text] [Related]
13. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
Frias JP; Yu JG; Kruszynska YT; Olefsky JM
Diabetes Care; 2000 Jan; 23(1):64-9. PubMed ID: 10857970
[TBL] [Abstract][Full Text] [Related]
14. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
Maggs DG; Buchanan TA; Burant CF; Cline G; Gumbiner B; Hsueh WA; Inzucchi S; Kelley D; Nolan J; Olefsky JM; Polonsky KS; Silver D; Valiquett TR; Shulman GI
Ann Intern Med; 1998 Feb; 128(3):176-85. PubMed ID: 9454525
[TBL] [Abstract][Full Text] [Related]
15. Baseline factors affecting the efficacy of troglitazone on plasma glucose in Japanese patients with non-insulin-dependent diabetes mellitus.
Kuzuya T; Kosaka K; Akanuma Y; Shigeta Y; Kaneko T
Diabetes Res Clin Pract; 1998 Aug; 41(2):121-9. PubMed ID: 9789718
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
Inzucchi SE; Maggs DG; Spollett GR; Page SL; Rife FS; Walton V; Shulman GI
N Engl J Med; 1998 Mar; 338(13):867-72. PubMed ID: 9516221
[TBL] [Abstract][Full Text] [Related]
17. Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control.
Gavin LA; Barth J; Arnold D; Shaw R
Endocr Pract; 2000; 6(4):305-10. PubMed ID: 11242607
[TBL] [Abstract][Full Text] [Related]
18. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
19. Improvement of liver function parameters in patients with type 2 diabetes treated with thiazolidinediones.
Ono M; Ikegami H; Fujisawa T; Nojima K; Kawabata Y; Nishino M; Taniguchi H; Itoi-Babaya M; Babaya N; Inoue K; Ogihara T
Metabolism; 2005 Apr; 54(4):529-32. PubMed ID: 15798962
[TBL] [Abstract][Full Text] [Related]
20. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
Kadoglou NP; Kapelouzou A; Tsanikidis H; Vitta I; Liapis CD; Sailer N
Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):63-8. PubMed ID: 21031343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
